SciELO - Scientific Electronic Library Online

vol.29 número2Complicaciones del tratamiento quirúrgico tras radioterapia y quimioterapia neoadyuvantes en el cáncer no microcítico de pulmón: Análisis de una serie de 16 pacientes índice de autoresíndice de materiabúsqueda de artículos
Home Pagelista alfabética de revistas  

Servicios Personalizados




Links relacionados


Oncología (Barcelona)

versión impresa ISSN 0378-4835


COBO DOLS, M. et al. New prospects in non-small cell lung cancer treatment: pharmacogenomics. Oncología (Barc.) [online]. 2006, vol.29, n.2, pp.13-22. ISSN 0378-4835.

The most commonly used chemotherapy strategy in advanced non-small cell lung cancer (NSCLC) today is the combination of two drugs, mainly cisplatin with another drug (gemcitabine, vinorelbine, taxanes, irinotecan). In the last decade attempts have been made to overcome chemotherapy resistance without benefit in outcome. There is a "plateau" in the results which seems unable to progress beyond the frontier of 8-10 months of median survival. At present, research in cancer survival is focused on translational pharmacogenomics, with the goal of providing individualized CT based on different genetic traits, such a polymorphisms, gen mutation and overexpresion of drug target gene transcripts, and several molecular assays can been used to tailor chemotherapy in the care of lung cancer patients. Accumulated evidence indicates that many genetic markers are related to chemotherapy resistance. One of the most important goals in translational research is to investigate the clinical use of the DNA repair pathways. Several genes such as ERCC1, XPD polymorphisms. RRM1, BCRA1, etc are related to cisplatin and other drugs resistance.

Palabras clave : Non-small cell lung cancer; Chemotherapy; Pharmacogenomics.

        · resumen en Español     · texto en Español     · Español ( pdf )


Creative Commons License Todo el contenido de esta revista, excepto dónde está identificado, está bajo una Licencia Creative Commons